RGS1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation

Abstract

Background Effective treatment is needed for advanced, inoperable, or chemotherapy-resistant cervical cancer patients. Immunotherapy has become a new treatment modality for cervical cancer patients, and there is an urgent need to identify additional targets for cervical cancer immunotherapy. Methods In this study the core gene, RGS1, which affects immune status and the FIGO stage of cervical cancer patients was identified by WGCNA analysis and differential analysis using TCGA database. 10 related genes interacting with RGS1 were identified using PPI network, and the functional and immune correlations were analyzed. Based on the expression of RGS1 and related genes, the consensus clustering method was used to divide CESC patients into two groups (group 1, high expression of RGS1; group 2, low expression of RGS1). Then, the functional enrichment analysis was used to search for the functional differences in differentially expressed genes (DEGs) between group 1 and group 2. Immune infiltration analysis was performed using ESTIMATE, CIBERSORT, and ssGSEA, and the differences in expression of immune checkpoint inhibitors (ICIs) targets were assessed between the two groups. We investigated the effect of RGS1 on the clinical relevance of CESC patients, and experimentally verified the differences in RGS1 expression between cervical cancer patient tissues and normal cervical tissues, the role of RGS1 in cell function, and the effect on tumor growth in tumor-bearing mice. Results We found that RGS1 was associated with CD4, GNAI3, RGS2, GNAO1, GNAI2, RGS20, GNAZ, GNAI1, HLA-DRA and HLA-DRB1, especially CD4 and RGS2. Functional enrichment of DEGs was associated with T cell activation. Compared with group 2, group 1 had stronger immune infiltration and higher ICI target expression. RGS1 had higher expression in cervical cancer tissues than normal tissues, especially in HPV-E6 positive cancer tissues. In cervical cancer cell lines, knockdown of RGS1 can inhibited cell proliferation, migration, invasion, and tumor growth in nude mice and promoted apoptosis. Conclusions RGS1, as an oncogenic gene of cervical cancer, affects the immune microenvironment of patients with cervical cancer and may be a target of immunotherapy.

Integrated single-cell and bulk RNA sequencing analysis identifies the predictive signature for prognosis and neoadjuvant chemotherapy responses in breast cancer

“…2G-J). Speci cally, RGS1 was also speci cally expressed in T cell clusters, and a previous study has supported that RGS1 was associated with CD4 expression and was functionally associated with T cell activation [20]. The expression activity of the 190 key genes was calculated using the R package AUCell and showed a bimodal distribution among all cells (Fig.…”

Identification of DNA methylation-regulated differentially expressed genes in RA by integrated analysis of DNA methylation and RNA-Seq data

“…Subsequently, the adjacency matrix was transformed into a topological overlap matrix (TOM), and the corresponding dissimilarity (1-TOM) was calculated. The dynamic tree cut method was performed to identify the module by hierarchically clustering genes [ 12 ]. The minModuleSize = 25.…”

RGS proteins and their roles in cancer: friend or foe?

“…In addition, the expression of RGS12 is significantly reduced in oral squamous cell carcinoma (OSCC) tissues, and overexpression of RGS12 represses OSCC cell proliferation and migration through regulating the phosphorylation and SUMOylation of phosphatase and tension homolog (PTEN) [ 112 ]. Conversely, the expression of RGS1 is observed to be aberrantly up-regulated in gastric cancers and cervical cancers with poor prognosis in patients [ 139 , 140 ]. In addition, the increased levels of RGS20 is correlated with tumor progression and unfavorable clinical outcome in penile cancer, where overexpression of RGS20 potentiates penile cancer progression through modulating the activity of PI3K/AKT signaling [ 141 ].…”